A/Prof Helen Wheeler
Medical Oncologist, special interest in neuro-oncology and clinical trials
“Adrenal cancer is an extremely rare cancer with limited treatment options and poor survival rates. We are working on a new drug therapy which directly kills the cancer cells, stops the cancer spreading and reduces the risk of damage to other organs, including the liver.”
Professor Stan Sidhu
Professor of Surgery at the Northern Clinical School and Kolling Institute of Medical Research
CLINICAL TRIAL: PARTICIPANTS WITH ADVANCED CANCER, NO CURATIVE TREATMENT OPTIONS
Prof Stan Sidhu (Professor of Surgery, Head of the University of Sydney Endocrine Surgical Unit) and his team have conducted a clinical trial; A study of EnGeneIC Dream Vectors (EDV’s) packaged with the chemotherapy PNU-159682, given simultaneously as non-targeted EDVs carrying an immune enhancer called EDVs40-mer, in participants with advanced cancer who have no curative treatment options.
Trail ID: ACTRN12617000037303